Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Sanofi

New sleeping sickness pill gets nod, paving the way for use in Africa

European drug regulators are endorsing a new and simpler treatment for sleeping sickness, in what could be a giant boost to efforts to eliminate the disease

The Independent UK

Sanofi CEO: The enterprise AI shift will reshape pharma in 2026

At Sanofi, AI has shifted from experimentation to becoming a vital part of our infrastructure.

Fortune

Flu Season's Here—This Dividend-Payer Controls the Shot Market

With flu season in full swing, drugmakers are hoping for a short-term tailwind after a lackluster 2025. Sanofi could be the winning ticket.

MarketBeat

From analysis to the latest developments in health,
read the most diverse news in one place.

Despite Trump pressure, Big Pharma is raising hundreds of drug prices

Costs of at least 350 branded medications, including vaccines against Covid-19, shingles and cancer treatment Ibrance, will reportedly be hiked

The Independent UK

FDA opens safety review of injectable RSV drugs approved for babies and toddlers

Federal health officials are reviewing the safety of two injectable drugs used to protect babies and toddlers from the RSV virus

The Independent UK

Drugmakers Briefed As Vaccine Skeptics Like RFK Jr. Probe RSV Therapy Risks

U.S. regulators are taking a fresh look at infant respiratory syncytial virus (RSV) antibody treatments after concerns raised by vaccine skeptics prompted Robert F. Kennedy Jr.'s health leadership team to initiate new safety inquiries.

Benzinga

Under the Radar: Why This 600M Fund Manager Keeps Outperforming Wall Street

While everyone else is running in circles over the next week breathlessly talking about what Buffett, Ackman, Pabrai and Woods are buying, I will be calmly going through the 13f filings of obscure money managers who know one has heard of, have little to no social media presence

Benzinga

Read news from The Economist, FT, and more,
with one subscription

French bosses parade choice of investing billions in homegrown firms

French companies announced investments worth €9.2 billion on Monday at the first edition of a government-backed "Choose France" summit dedicated to domestic firms. The government is keen to show the euro zone’s second-biggest economy remains a top business destination despite political turmoil.

Radio France Internationale

Dupixent Pushes Sanofi's Quarterly Sales Past $14.5 Billion Mark

Sanofi SA (NASDAQ:SNY) reported third-quarter sales of $14.55 billion (12.43 billion euros), beating the consensus of $14.46 billion. Sales increased 2.3% year over year, up 7% in constant currency.

Benzinga

Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy

Sanofi SA (NASDAQ:SNY) on Wednesday revealed topline data from the ElevAATe phase 2 study of efdoralprin alfa (SAR447537, formerly known as INBRX-101), for alpha-1 antitrypsin deficiency (AATD) emphysema.

Benzinga

Sanofi's Rezurock Approval Stumbles In EU For Chronic Graft-Vs-Host Disease

On Friday, the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) issued a negative opinion for Sanofi SA’s (NASDAQ:SNY) Rezurock (belumosudil).

Benzinga

Sanofi AlphaMedix Study Hits Key Milestones In Phase 2 Study

Sanofi SA (NASDAQ:SNY) on Wednesday released topline data from a phase 2 study evaluating the efficacy and safety of AlphaMedix (212Pb-DOTAMTATE).

Benzinga

Sanofi Expands Insulin Savings Program To Cover All US Patients

The U.S. Food and Drug Administration removed the Risk Evaluation and Mitigation Strategies (REMS) program for Caprelsa (vandetanib), a thyroid cancer medication manufactured by Sanofi SA’s (NASDAQ: SNY) Genzyme Corporation.

Benzinga

FDA Delays Key Sanofi Multiple Sclerosis Drug Decision

On Monday, the U.S. Food and Drug Administration (FDA) extended the review date for Sanofi SA’s (NASDAQ:SNY) new drug application (NDA) of tolebrutinib for non-relapsing, secondary progressive multiple sclerosis (nrSPMS) and to slow disability accumulation independent of relapse activity in adult patients.

Benzinga

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Sanofi Reports Early Brivekimig Data, Signals Strong Efficacy And Good Tolerability

Sanofi SA (NASDAQ:SNY) shared new data from the HS-OBTAIN phase 2a study, which shows that treatment with brivekimig led to clinically meaningful improvements in the primary endpoint of Hidradenitis Suppurativa Clinical Response (HiSCR50) in patients naïve to biologics with moderate-to-severe hidradenitis suppurativa (HS).

The Guardian - UK

Britain is ‘a terrible place’ to sell medicines, says drug firm executive

Sanofi’s market access chief urges ministers to come up with a roadmap to raise spending on new treatments

Benzinga

Roblox To Rally Around 34%? Here Are 10 Top Analyst Forecasts For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.

Benzinga

This Veeva Systems Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

Get all your
news in one place.

100's of premium titles.
One news app.

Benzinga

Why Is Sanofi Stock Falling Thursday?

On Thursday, Sanofi SA (NASDAQ:SNY) stock tumbled after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Benzinga

Sanofi Hit With Shock As Flagship Drug Successor Disappoints Investors

French drugmaker Sanofi SA (NASDAQ:SNY) stock fell sharply Thursday after late-stage trial results for amlitelimab, its potential successor to blockbuster eczema drug Dupixent, failed to match investor expectations, raising fresh doubts about the company’s ability to sustain its dermatology franchise once patent protections expire.

Fortune

AI might beat IQ, not EQ — but never say never

We underestimate the scale of the AI learning curve, says Paul Hudson, CEO of Sanofi.

Benzinga

Sanofi, Eli Lilly, Novo Nordisk, AstraZeneca Face Renewed Claims Of Conspiring To Restrict 340B Discounts

A federal appeals court has revived a proposed class action accusing four major drugmakers of conspiring to restrict a government-mandated drug discount program, allegedly driving up costs for safety-net hospitals and clinics serving low-income patients.

Benzinga

Options Corner: Sanofi's Post-Earnings Drama Delivers A Contrarian Discount

With investors concerned about overall economic stability amid the Trump administration's tariff impact, they're not in a particularly generous mood. That may be the lesson learned the hard way by global pharmaceutical giant Sanofi SA (NASDAQ:SNY). Despite delivering an earnings report that offered an encouraging view, it wasn't a perfect…

Benzinga

Sanofi's Q2 Earnings Fall Short On Expectations Despite 21% Jump In Dupixent Sales

Sanofi SA (NASDAQ:SNY) reported second-quarter sales of $11.33 billion (€9.99 billion euros), narrowly missing the consensus of $11.53 billion.

Benzinga

Why Thermo Fischer Stock Is Rising Wednesday

Thermo Fisher Scientific Inc. (NYSE:TMO) on Wednesday reported second-quarter 2025 adjusted earnings of $5.36 per share, beating the street view of $5.23.

1 2 3 4 5

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.